Skip to main content
Lyka Labs Ltd. logo

Lyka Labs Ltd. — Investor Relations & Filings

Ticker · LYKALABS ISIN · INE933A01014 LEI · 3358001RHQJBCTT1ER45 BSE.NS Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2020-08-07 Regulatory Filings
Country IN India
Listing BSE.NS LYKALABS

About Lyka Labs Ltd.

https://www.lykalabs.com

Lyka Labs Ltd. specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, dermatologicals, cardiovascular agents, and pain management. A significant area of expertise for the organization is lyophilization technology, enabling the production of high-quality injectable formulations. The company operates advanced manufacturing facilities designed to meet international quality standards, supporting its operations in both domestic and global markets. Its core activities encompass the production of various dosage forms such as tablets, capsules, ointments, and sterile injectables, with a particular focus on specialized segments like cephalosporins and critical care medications.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings
2020-08-07 English
Financial Result Updates
Regulatory Filings
2020-08-07 English
Book Closure for the purpose of AGM to be held on 25th September, 2020.
Regulatory Filings
2020-08-07 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement dated 7th August 2020 from Lyka Labs Limited regarding the outcome of a Board Meeting. It includes approval of unaudited standalone and consolidated financial results for the quarter ended 30th June 2020, along with the limited review report by statutory auditors. The document contains comprehensive financial data for the quarter, notes on the financial results, and an independent auditor's review report. The presence of detailed financial statements, notes, and auditor's review indicates this is a quarterly financial report. The document is about 15,000 characters long, which is substantial and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2020-08-07 English
Outcome of Board Meeting held on 7th August, 2020 1. Approved Un-audited Standalone Financial Results for the quarter ended 30th June, 2020 and noted Iimited review report provided ....
Regulatory Filings
2020-08-07 English
Board Meeting — Financial Results
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 60 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, no report content, no announcements, or any other information to classify as a specific report type. Given the lack of content, the document best fits the fallback category for miscellaneous or non-classifiable filings, which is Regulatory Filings (RNS).
2020-07-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.